Advanced Antibody–Drug Conjugates Design: Innovation in Linker Chemistry and Site‐Specific Conjugation Technologies
ChemBioChem · 17.11.2025 · 26 (22)
DOI: 10.1002/cbic.202500305 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemBioChem, online erschienen am 26.09.2025. Verfasst von Yutaka Matsuda und 2 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Biotherapeutics, Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, CA, 94502, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Drug Design, Antineoplastic Agents, Antibodies, Monoclonal. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 100 Literaturangaben.
Abstract (Originalsprache)
Antibody–drug conjugates (ADCs) represent a promising class of targeted cancer therapies, with the potential to improve treatment precision because of their unique mechanism of selectively delivering cytotoxic payloads (PLs) to tumor cells. ADCs combine a monoclonal antibody directed against a tumor‐associated antigen with a potent cytotoxic PL via a covalent linker which connects the PL to the antibody. Several ADCs have been approved for clinical use in oncology, including Mylotarg, Adcetris, Kadcyla, Besponsa, Polivy, Lumoxiti, Padcev, Enhertu, Trodelvy, Aidixi, Zynlonta, Tivdak, Elahere, Datroway, and Emrelis. This review focuses on recent advances in linker chemistry and site‐specific conjugation technologies, which are critical for optimizing ADC design and improving therapeutic indices. The development of next‐generation ADCs has focused on overcoming challenges related to linker stability, efficiency of target antigen internalization, and pharmacokinetics. Traditional conjugation methods, such as lysine or cysteine conjugation, have been widely used but are associated with inherent issues of heterogeneity and instability. Advances in linker chemistry, such as the development of novel cleavable linkers, have significantly contributed to the clinical success of ADCs. In this review, different linker components are discussed, including chemical handles for conjugation, spacers to improve hydrophobicity, and triggers for PL release. In addition, innovative conjugation strategies are highlighted, which enhance ADC homogeneity and stability. The site‐specific conjugation and therapeutic performance benefits of technologies such as THIOMAB, SMARTag, microbial transglutaminase, glycan remodeling, and AJICAP are discussed. The toxicity profiles of ADCs and strategies are also addressed to mitigate off‐target effects and systemic toxicity. Overall, this review provides a comprehensive overview of the current state of linker and conjugation technologies in ADC development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discovery Biotherapeutics, Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, CA, 94502, USA.
ORCID-Profile: Yutaka Matsuda, Brian A Mendelsohn
Zitieren
APA
Matsuda, Y., Chang, J. R., & Mendelsohn, B. A. (2025). Advanced Antibody–Drug Conjugates Design: Innovation in Linker Chemistry and Site‐Specific Conjugation Technologies. ChemBioChem, 26(22). https://doi.org/10.1002/cbic.202500305
Vancouver
Matsuda Y, Chang JR, Mendelsohn BA. Advanced Antibody–Drug Conjugates Design: Innovation in Linker Chemistry and Site‐Specific Conjugation Technologies. ChemBioChem. 2025;26(22). doi:10.1002/cbic.202500305
BibTeX
@article{Matsuda2025,
author = {Matsuda, Yutaka and Chang, Jenny R and Mendelsohn, Brian A},
title = {Advanced Antibody–Drug Conjugates Design: Innovation in Linker Chemistry and Site‐Specific Conjugation Technologies},
journal = {ChemBioChem},
year = {2025},
volume = {26},
number = {22},
doi = {10.1002/cbic.202500305}
}
EUVIMED